Codex
Governance grade: B+ because controls and board independence are strong, but insider alignment is driven more by compensation grants than open-market insider buying.
The People Running This Company
CEO Tenure (Years)
CFO Tenure (Years)
Independent Chair Tenure (Years)
New Directors Since 2022
Leadership quality looks credible and stable, with meaningful institutional knowledge across CEO, CFO, and CRO seats. The main trust question is not capability; it is whether internal succession depth and board challenge stay robust as long-tenured leaders and directors remain central.
What They Get Paid
CEO Pay Used in SEC Pay Ratio
Median Employee Pay
CEO-to-Median Pay Ratio
Pay is high in absolute dollars but structurally equity-heavy and tied to variable performance elements, which is appropriate for a large insurer with complex risk balance sheets. The key test is sustained return quality; if ROE stays below management's medium-term target range, current pay levels should face tougher scrutiny.
Are They Aligned?
Skin-in-the-Game Score (1-10)
Related-party risk appears controlled on disclosed evidence: the proxy describes a formal governance committee review framework and states there were no related-person transactions requiring Item 404 disclosure since January 1, 2024. On dilution behavior, compensation includes significant equity awards, but this has so far been offset by large buybacks and sustained common dividends.
Board Quality
Independent Directors
Directors With >10Y Tenure
Separate CEO/Chair
Independent Committee Chairs
Board quality is above average for formal independence and committee structure, and recent refresh actions are real rather than cosmetic. The practical concern is tenure concentration at the top of the board: independence on paper is strong, but sustained challenge quality depends on how newer directors influence key risk and compensation decisions.
The Verdict
Governance Grade: B+ (Score/100)
Skin-in-the-Game Score
Real concerns: insider activity is mostly grant mechanics rather than discretionary buying, and board tenure concentration raises a medium-term challenge-risk issue despite formal independence.
Most likely upgrade trigger: meaningful open-market insider buying alongside sustained ROE delivery within management targets. Most likely downgrade trigger: rising litigation/regulatory costs or governance complacency while pay remains elevated versus returns.